Cindy Cai, MD, shared insights from her presentation from ASRS 2023, "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.
Sheryl Stevenson
Advertisement
Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of Ophthalmology Times, Ophthalmology Times Europe, Modern Retina and Optometry Times. Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.
Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s EMPOWER Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.
In addition, she has served as a judge for Crain's Cleveland Business Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.
Articles by Sheryl Stevenson
Dr Ala Moshiri provides an overview of current treatment options for diabetic macular oedema.
Ala Moshiri, MD, PhD, provides an overview of current treatment options for diabetic macular edema.
The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal.
Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, United States, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.
Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.
Prof Anat Loewenstein, Chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), comments on the significance of the US FDA approval of aflibercept for preterm infants with retinopathy.
The company anticipates introducing latanoprost ophthalmic solution 0.005% to U.S. eye care practitioners in the second half of 2023.
At AAO 2022, Dr Mitch Shultz provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.
At AAO 2022, Dr Justis Ehlers presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.
Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.
Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Dr Sunir J. Garg explains how retinal surgeons can remove the vitreous gel with more efficiency.
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
This new surgical technique offers precision down to the micron level, which is more precise than a surgeon can achieve by themselves.
At Angiogenesis, Dr SriniVas R. Sadda discusses how choriocapillaris may predict the rate of progression of atrophy.
Dr Nadia K. Waheed reviews the latest updates on the FOCUS trial, evaluating AAV-based viral vector GT005 for the treatment of geographic atrophy.
Dr David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
Advertisement
Advertisement
Advertisement
